DURECT Corp (DRRX)-医療機器分野:企業M&A・提携分析

◆英語タイトル:DURECT Corp (DRRX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8013836
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
DURECT Corp (Durect) is a specialty pharmaceutical company. It carries out the development of pharmaceutical systems based on its proprietary drug delivery technology platforms to treat chronic debilitating diseases. It also undertakes the development of biotechnology products. The company’s major products include Alzet, an osmotic pump; and Lactel, a biodegradable polymer. The company’s product pipeline comprises DUR-928 indicated for treatment of acute organ injuries and metabolic/lipid disorders; Remoxy, indicated for chronic pain; Posimir, indicated for post-operative pain; Eladur, indicated for post herpetic neuralgia; Oradur, indicated for chronic pain and attention deficit hyperactivity disorder; and Relday, indicated for Schizophrenia and bipolar disorder. Durect’s major drug delivery technology platforms include Saber, Cloud, Oradur and Transdur. The company operates in the US, Europe, Japan and other countries. Durect is headquartered in California, the US.

DURECT Corp (DRRX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
DURECT Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
DURECT Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 6
DURECT Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
DURECT Corp, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
DURECT Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
DURECT Corp, Medical Equipment, Deal Details 10
Partnerships 10
Durect Enters into Licensing Agreement with Santen Pharma 10
Durect Enters Into Licensing Agreement with Virginia Commonwealth University Intellectual Property Foundation 11
Equity Offering 12
Durect Files Registration Statement For Public Offering Of Securities For US$100.9 Million 12
Durect Files Registration Statement For Public Offering Of Common Stock For Up To US$25 Million 13
Durect Completes Public Offering Of Shares For US$11.5 Million 14
Durect Completes Public Offering Of Shares For US$13 Million 15
DURECT Corp – Key Competitors 16
DURECT Corp – Key Employees 17
DURECT Corp – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Financial Announcements 19
Nov 01, 2017: DURECT Announces Third Quarter 2017 Financial Results and Provides Corporate Update 19
Aug 08, 2017: DURECT Announces Second Quarter 2017 Financial Results and Provides Corporate Update 21
May 10, 2017: DURECT Announces First Quarter 2017 Financial Results and Provides Corporate Update 23
Mar 14, 2017: DURECT Announces Fourth Quarter and Full Year 2016 Financial Results and Update of Programs 25
Oct 31, 2016: DURECT Announces Third Quarter 2016 Financial Results and Update of Programs 27
Aug 01, 2016: DURECT Announces Second Quarter 2016 Financial Results and Update of Programs 29
May 05, 2016: DURECT Announces First Quarter 2016 Financial Results and Update of Programs 31
Feb 29, 2016: DURECT Announces Fourth Quarter 2015 Financial Results and Update of Programs 33
Corporate Communications 35
Sep 20, 2017: DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
DURECT Corp, Medical Equipment, Key Facts, 2016 2
DURECT Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
DURECT Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
DURECT Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 6
DURECT Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
DURECT Corp, Deals By Market, 2011 to YTD 2017 8
DURECT Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Durect Enters into Licensing Agreement with Santen Pharma 10
Durect Enters Into Licensing Agreement with Virginia Commonwealth University Intellectual Property Foundation 11
Durect Files Registration Statement For Public Offering Of Securities For US$100.9 Million 12
Durect Files Registration Statement For Public Offering Of Common Stock For Up To US$25 Million 13
Durect Completes Public Offering Of Shares For US$11.5 Million 14
Durect Completes Public Offering Of Shares For US$13 Million 15
DURECT Corp, Key Competitors 16
DURECT Corp, Key Employees 17

★海外企業調査レポート[DURECT Corp (DRRX)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Oil & Gas Development Co Ltd (OGDC):企業の財務・戦略的SWOT分析
    Oil & Gas Development Co Ltd (OGDC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Casey’s General Stores, Inc. (CASY):企業の財務・戦略的SWOT分析
    Casey's General Stores, Inc. (CASY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Michael J Fox Foundation for Parkinson’s Research-医療機器分野:企業M&A・提携分析
    Summary Michael J Fox Foundation for Parkinson's Research (Michael J. Fox) is a research foundation that conducts research on Parkinson's disease. The foundation offers research and development of therapies. It provides drug development and other research activities in the area of Parkinson's diseas …
  • Alberta Health Services:企業の戦略的SWOT分析
    Alberta Health Services - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Thryv Holdings Inc (THRY):企業の財務・戦略的SWOT分析
    Thryv Holdings Inc (THRY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Atmos Energy Corporation (ATO):石油・ガス:M&Aディール及び事業提携情報
    Summary Atmos Energy Corp (Atmos Energy) is a fully-regulated natural gas distributor. Together with its subsidiaries, the company delivers natural gas through regulated sales and transportation arrangements to residential, commercial, public authority and industrial customers.The company is also in …
  • Unity Biotechnology Inc (UBX):製薬・医療:M&Aディール及び事業提携情報
    Summary Unity Biotechnology Inc (Unity Biotechnology), formerly Forge Inc is a biotechnology company that researches, develops and commercializes therapeutics for the treatment of age-related diseases. The company focuses on the development of senolytic medicines to eliminate senescent cells. The co …
  • Obsidian Energy Ltd (OBE):石油・ガス:M&Aディール及び事業提携情報
    Summary Obsidian Energy Ltd (Obsidian) is formerly known as Penn West Petroleum Ltd. It is a conventional oil and natural gas production and development company in Canada with a well-balanced portfolio of high-quality assets. It develops and explores oil and gas properties and related production inf …
  • Hokuriku Electric Power Co (9505):企業の財務・戦略的SWOT分析
    Hokuriku Electric Power Co (9505) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Bavarian Nordic AS (BAVA):製薬・医療:M&Aディール及び事業提携情報
    Summary Bavarian Nordic A/S (Bavarian Nordic) is a biotechnology company that develops, manufactures and commercializes cancer immunotherapies and vaccines for infectious diseases. The company develops its products using poxvirus-based technology platforms including vaccinia-fowlpox (VF)-TRICOM and …
  • Mitsubishi Motors Corporation (7211):企業の財務・戦略的SWOT分析
    Mitsubishi Motors Corporation (7211) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Huesker Synthetic Gmbh
    Huesker Synthetic Gmbh - Strategy, SWOT and Corporate Finance Report Summary Huesker Synthetic Gmbh - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Clariant Ltd.:企業の戦略・SWOT・財務情報
    Clariant Ltd. - Strategy, SWOT and Corporate Finance Report Summary Clariant Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Vitro, S.A.B. de C.V.:企業の戦略・SWOT・財務情報
    Vitro, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report Summary Vitro, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Fichtner GmbH & Co KG:企業の戦略的SWOT分析
    Fichtner GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • NovoCure Ltd (NVCR):企業の財務・戦略的SWOT分析
    Summary NovoCure Ltd (NovoCure) is an drug company that offers development and commercialization of novel therapies for tumor treating fields. The company’s pipeline products find application in cancer indications such as malignant melanoma, hepatocellular carcinoma, ovarian cancer, breast cancer an …
  • Siam Makro Public Company Limited (MAKRO):企業の財務・戦略的SWOT分析
    Siam Makro Public Company Limited (MAKRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Simplex Infrastructures Limited:戦略・SWOT・企業財務分析
    Simplex Infrastructures Limited - Strategy, SWOT and Corporate Finance Report Summary Simplex Infrastructures Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • InBios International Inc:企業の製品パイプライン分析
    Summary InBios International Inc (InBios International) is a medical device company that develops, manufactures and markets medical diagnostic tests for detecting infectious diseases. The company offers products such as assays, ELISA kits, rapid immunoassays, veterinary products, and monoclonal anti …
  • Cypark Resources Berhad (CYPARK):企業の財務・戦略的SWOT分析
    Summary Cypark Resources Berhad (CRB) is a clean technology company that offers environmental engineering services. The company offers engineering and technology services on transforming dump sites to an economic and environmental boon. Its services include environmental remediation, integrated wast …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆